论文部分内容阅读
目的:探讨不同乙肝治疗方法对于乙肝合并肺结核患者抗结核治疗中的肝功保护作用。方法:选择2015年08月至2016年08月期间我院收治的120例乙肝合并肺结核患者作为研究对象,将给予常规抗肝炎治疗的40例患者作为本次研究的对照组,在对照组的基础上给予拉米夫定抗病毒治疗的40例患者作为A组,其余在对照组的基础上增加抗纤维化治疗的40例患者作为B组,观察各组患者的肝功保护作用。结果:治疗后A组和B组患者的ALT、AST、TBIL等指标均显著优于对照组,差异有统计学意义(P<0.05);三组的停药率比较无统计学意义(P>0.05)。结论:在不同乙肝治疗方法中抗病毒治疗对乙肝合并肺结核患者抗结核治疗中的具有肝功保护作用,值得推广。
Objective: To investigate the protective effects of different hepatitis B treatments on liver function in anti-TB treatment of hepatitis B patients with pulmonary tuberculosis. Methods: From August 2015 to August 2016, 120 patients with hepatitis B combined with tuberculosis admitted to our hospital from August 2015 to August 2016 were enrolled. Forty patients with routine anti-hepatitis treatment were selected as the control group and the control group Forty patients with lamivudine antiviral therapy were enrolled in group A, and the other 40 patients treated with antifibrotic therapy as the control group were selected as group B to observe the protective effect of liver function in each group. Results: After treatment, the indexes of ALT, AST and TBIL in group A and group B were significantly better than those in control group (P <0.05), and the withdrawal rates in the three groups were not statistically significant (P> 0.05). CONCLUSION: Antiviral therapy in different hepatitis B treatments has the protective effect on liver function in the anti-TB treatment of patients with hepatitis B and pulmonary tuberculosis, which is worth promoting.